Literature DB >> 23441239

An Investigator-initiated Study to Assess the Safety and Efficacy of Imiquimod 3.75% Cream When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses on Dorsal Hands and Forearms.

Gary Goldenberg1, Rita V Linkner, Giselle Singer, Amylynne Frankel.   

Abstract

OBJECTIVE: To evaluate the efficacy of combination cryotherapy and imiquimod 3.75% cream versus cryotherapy alone in the treatment of hypertrophic actinic keratosis on the dorsal hand and forearm.
METHODS: Twenty subjects with at least three hypertrophic actinic keratoses on each dorsal hand or forearm underwent cryotherapy treatment to hypertrophic actinic keratoses. Following cryotherapy, subjects were randomized to have either their right or left dorsal hand or forearm treated with imiquimod 3.75% cream to begin on the same day as cryotherapy treatment. Subjects then utilized the two weeks on, two weeks off, two weeks on regimen of imiquimod 3.75% cream application. Local skin reactions were also assessed.
RESULTS: For the cryotherapy/imiquimod 3.75% arm, the median total hypertrophic actinic keratosis reduction was -5.12 and for the cryotherapy alone arm, the median total hypertrophic actinic keratosis reduction was -2.24 (P<0.0094). LIMITATIONS: Local skin reactions unbind the investigator.
CONCLUSION: Cryotherapy plus imiquimod 3.75% cream resulted in a statistically significant improvement in the reduction of hypertrophic actinic keratoses than cryotherapy alone at 14 weeks.

Entities:  

Year:  2013        PMID: 23441239      PMCID: PMC3579487     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  21 in total

1.  Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies.

Authors:  John Geisse; Ivor Caro; Jane Lindholm; Loren Golitz; Patti Stampone; Mary Owens
Journal:  J Am Acad Dermatol       Date:  2004-05       Impact factor: 11.527

2.  Chronic neuropathic pain associated with imiquimod: report of 2 cases.

Authors:  B Alexander Yi; Melissa J Nirenberg; Sanford M Goldstein; Timothy G Berger
Journal:  J Am Acad Dermatol       Date:  2005-02       Impact factor: 11.527

3.  Efficacy of imiquimod as an adjunct to cryotherapy for actinic keratoses.

Authors:  Jerry K L Tan; D Richard Thomas; Yves Poulin; Frances Maddin; Jing Tang
Journal:  J Cutan Med Surg       Date:  2007 Nov-Dec       Impact factor: 2.092

4.  Severe systemic reaction to topical imiquimod.

Authors:  Anna-Kaisa Heikkinen; Päivikki Susitaival
Journal:  Acta Derm Venereol       Date:  2011-09       Impact factor: 4.437

5.  A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses.

Authors:  Eggert Stockfleth; Thomas Meyer; Bernd Benninghoff; Stuart Salasche; Latza Papadopoulos; Claas Ulrich; Enno Christophers
Journal:  Arch Dermatol       Date:  2002-11

6.  Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification.

Authors:  D Goldstein; P Hertzog; E Tomkinson; D Couldwell; S McCarville; S Parrish; P Cunningham; M Newell; M Owens; D A Cooper
Journal:  J Infect Dis       Date:  1998-09       Impact factor: 5.226

7.  Development of a treatment algorithm for actinic keratoses: a European Consensus.

Authors:  Eggert Stockfleth; Carlos Ferrandiz; Jean Jacques Grob; Irene Leigh; Hubert Pehamberger; Helmut Kerl
Journal:  Eur J Dermatol       Date:  2008-10-27       Impact factor: 3.328

8.  A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up.

Authors:  N Krawtchenko; J Roewert-Huber; M Ulrich; I Mann; W Sterry; E Stockfleth
Journal:  Br J Dermatol       Date:  2007-12       Impact factor: 9.302

9.  Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head.

Authors:  E Stockfleth; W Sterry; M Carey-Yard; J Bichel
Journal:  Br J Dermatol       Date:  2007-12       Impact factor: 9.302

Review 10.  Mechanism of action and other potential roles of an immune response modifier.

Authors:  Anthony A Gaspari
Journal:  Cutis       Date:  2007-04
View more
  4 in total

Review 1.  Actinic keratosis: update on field therapy.

Authors:  Gary Goldenberg; Marcel Perl
Journal:  J Clin Aesthet Dermatol       Date:  2014-10

2.  Assessment of local skin reactions with a sequential regimen of cryosurgery followed by ingenol mebutate gel, 0.015%, in patients with actinic keratosis.

Authors:  Gary Goldenberg; Brian Berman
Journal:  Clin Cosmet Investig Dermatol       Date:  2014-12-16

Review 3.  Toll-like receptor signalling in B cells during systemic lupus erythematosus.

Authors:  Simon Fillatreau; Benoît Manfroi; Thomas Dörner
Journal:  Nat Rev Rheumatol       Date:  2020-12-18       Impact factor: 20.543

Review 4.  Imiquimod - Its role in the treatment of cutaneous malignancies.

Authors:  Aditya Kumar Bubna
Journal:  Indian J Pharmacol       Date:  2015 Jul-Aug       Impact factor: 1.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.